Dr. Levine on Recent Progress in Cervical Cancer

Douglas A. Levine, MD
Published: Wednesday, Nov 23, 2016



Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.
 
The highlight of the progress in the treatment of this disease, says Levine, is in prevention, particularly with the HPV vaccine. He expects that we will see a dramatic decrease in cervical cancer diagnoses as more and more people continue to receive the HPV vaccine.
 
As for therapeutic advancements, Levine discusses effective treatments involving angiogenic inhibitors as well as the more novel PARP inhibitors.
 
While cervical cancer screening continues to be highly effective and helpful for patients, ovarian cancer screening still needs further development, says Levine. Overall, though, the treatment landscape is quickly changing, and Levine believes experts in this field are succeeding in helping their patients and advancing their mission.


Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.
 
The highlight of the progress in the treatment of this disease, says Levine, is in prevention, particularly with the HPV vaccine. He expects that we will see a dramatic decrease in cervical cancer diagnoses as more and more people continue to receive the HPV vaccine.
 
As for therapeutic advancements, Levine discusses effective treatments involving angiogenic inhibitors as well as the more novel PARP inhibitors.
 
While cervical cancer screening continues to be highly effective and helpful for patients, ovarian cancer screening still needs further development, says Levine. Overall, though, the treatment landscape is quickly changing, and Levine believes experts in this field are succeeding in helping their patients and advancing their mission.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x